Global Blood Therapeutics, Inc. (GBT): Price and Financial Metrics

Global Blood Therapeutics, Inc. (GBT)

Today's Latest Price: $66.90 USD

0.64 (-0.95%)

Updated Jul 7 4:00pm

Add GBT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

GBT Stock Summary

  • With a price/sales ratio of 253.66, Global Blood Therapeutics Inc has a higher such ratio than 98.38% of stocks in our set.
  • With a year-over-year growth in debt of 536.56%, Global Blood Therapeutics Inc's debt growth rate surpasses 96.77% of about US stocks.
  • Revenue growth over the past 12 months for Global Blood Therapeutics Inc comes in at 669.73%, a number that bests 99.06% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Global Blood Therapeutics Inc, a group of peers worth examining would be RESN, SAGE, EDIT, HRTX, and FGEN.
  • Visit GBT's SEC page to see the company's official filings. To visit the company's web site, go to
GBT Daily Price Range
GBT 52-Week Price Range

GBT Stock Price Chart Technical Analysis Charts

GBT Price/Volume Stats

Current price $66.90 52-week high $87.54
Prev. close $67.54 52-week low $39.95
Day low $66.88 Volume 462,704
Day high $68.95 Avg. volume 965,339
50-day MA $69.78 Dividend yield N/A
200-day MA $64.54 Market Cap 4.08B

Global Blood Therapeutics, Inc. (GBT) Company Bio

Global Blood Therapeutics is a clinical stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. The company was founded in 2012 and is based in San Francisco, California.

GBT Latest News Stream

Event/TimeNews Detail
Loading, please wait...

GBT Latest Social Stream

Loading social stream, please wait...

View Full GBT Social Stream

Latest GBT News From Around the Web

Below are the latest news stories about Global Blood Therapeutics Inc that investors may wish to consider to help them evaluate GBT as an investment opportunity.

GBT Awards $250,000 in ACCEL Grants to Advance Access to Care for People Living with Sickle Cell Disease

SOUTH SAN FRANCISCO, Calif., June 25, 2020 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that five U.S. nonprofit organizations serving the sickle cell.

Yahoo | June 25, 2020

Global Blood to Seek Approval of Oxbryta in Europe for SCD

Global Blood (GBT) plans to seek approval for Oxbryta tablets to treat hemolytic anemia in SCD patients aged 12 years and older in Europe.

Yahoo | June 25, 2020

Global Blood to file European application for Oxbryta for SCD anemia

Global Blood Therapeutics (GBT) intends to submit a marketing application in Europe seeking approval to use Oxbryta (voxelotor) to treat hemolytic anemia in patients at least 12 years old with sickle cell disease ((SCD)). It expects to complete the filing by mid-2021.Voxelotor inhibits hemoglobin polymerization, the root causes of the...

Seeking Alpha | June 24, 2020

GBT Announces Plans to Seek Regulatory Approval for Oxbryta® (voxelotor) to Treat Sickle Cell Patients in Europe

An oral, once daily therapy, Oxbryta directly inhibits hemoglobin polymerization, the root cause of the sickling and destruction of red blood cells in SCD. The sickling process causes hemolytic anemia (low hemoglobin due to red blood cell destruction), which impairs adequate oxygen delivery to the tissues and organs in the body.

Yahoo | June 24, 2020

Global Blood Therapeutics Inc (GBT): Hedge Funds In Wait-and-See Mode

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

Yahoo | June 19, 2020

Read More 'GBT' Stories Here

GBT Price Returns

1-mo 5.22%
3-mo 7.33%
6-mo -20.18%
1-year 22.96%
3-year 131.89%
5-year N/A
YTD -15.84%
2019 93.64%
2018 4.32%
2017 172.32%
2016 -55.30%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0974 seconds.